cefuroxime
Drug1500mg IV cefuroxime thrice daily during five days.
Other names: Zinacef
NCT Number: NCT05784311
The goal of this multicenter randomized controlled trial is to evaluate the additional value of pre-emptive antibiotic treatment on clinically relevant organ/space surgical site infections (OSIs) in patients undergoing pancreatoduodenectomy with a high risk for contaminated bile. The main objectives it aims to answer are:
* To evaluate the effect of pre-emptive antibiotic prophylaxis on clinically relevant OSIs in patients undergoing pancreatoduodenectomy with a high risk for contaminated bile * To evaluate the effect of pre-emptive antibiotic prophylaxis on other postoperative outcomes (e.g. OSIs, superficial SSIs, POPF, PPH, major morbidity, ICU admission, readmission, length of hospital stay, and mortality). * To evaluate concordance between perioperatively obtained bile cultures and postoperative cultures from infectious sites, and to evaluate antibiotic sensitivity patterns of the cultured microorganisms.
Participants will be randomized with a 1:1 allocation before surgery into the intervention or control group:
* Patients in the intervention group will receive perioperative prophylaxis (similar to the control group) followed by five days of 1500mg IV cefuroxime and 500mg IV metronidazole thrice daily. * Patients in the control group will only receive perioperative prophylaxis (a single dose of 5-7mg/kg gentamicin followed by 2gr IV cefazolin and 500mg IV metronidazole every 4h of surgery), which will be discontinued after surgery.
Interested in participating?
Request Info18 year–90 year
All sexes
Interventional
Phase 4
Leiden University Medical Center, Leiden, South Holland, Netherlands
Rationale: The additional value of pre-emptive antibiotic treatment after pancreatoduodenectomy is undetermined as previous research reported conflicting results regarding infectious complications. Prolonged antibiotic prophylaxis (formally pre-emptive antibiotic treatment) after pancreatoduodenectomy might reduce the rate of surgical site infections in patients with a high risk for contaminated bile (predominantly patients with preoperative biliary drainage or an ampullary malignancy). Current national and international guidelines lack clear recommendations regarding pre-emptive antibiotic treatment leading to substantially varying antibiotic prophylactic regimes between institutes.
Objective: This trial evaluates the additional value of pre-emptive antibiotic treatment on clinically relevant organ/space surgical site infections (OSIs) in patients undergoing pancreatoduodenectomy with a high risk for contaminated bile.
Study design: This multicenter, randomized controlled, superiority trial compares perioperative versus pre-emptive antibiotic treatment during five postoperative days after pancreatoduodenectomy in patients with a high risk for contaminated bile.
Study population: Adult patients undergoing pancreatoduodenectomy with a high risk for contaminated bile (patients with preoperative biliary drainage or an ampullary malignancy). Patients with a contraindication for the study antibiotics or a preoperative indication for antibiotics (e.g. cholangitis of preoperative abscesses) are excluded.
Intervention: Participants will be randomized to either perioperative prophylaxis (cefazolin, metronidazole and a single dose of 5-7mg/kg gentamicin, control arm) or additional cefuroxime and metronidazole for five postoperative days (experimental arm).
Main study endpoints: The primary endpoint are organ/space infections (OSIs) within 90 days after surgery requiring a therapeutic intervention. Secondary endpoints are OSIs, isolated OSIs, wound infections, postoperative pancreatic fistula, bile or enteric anastomotic leakage, post pancreatectomy hemorrhage, delayed gastric emptying, bacteremia, Clostridium difficile infection, major morbidity (Clavien-Dindo ≥III), reintervention, ICU admission, length of hospital stay, readmission, and in-hospital and 90-day mortality. Besides, switch of postoperative antibiotics, antibiotic sensitivity patterns and concordance between perioperative bile and postoperative surgical site cultures are analyzed.
Sample size: The sample size is calculated for superiority to achieve an OSI difference of 15% (40% vs 25%). With a 80% power (1-β) and a two-sided significance level (α) of 5.0%, a sample of 304 evaluable patients is required for superiority. Assuming a 3% non-resection rate due to metastatic disease and a 3% loss-of-follow-up rate, an expected number of 322 included patients are needed to reach the sample size of 304 evaluable patients to demonstrate superiority for the intervention.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1500mg IV cefuroxime thrice daily during five days.
Other names: Zinacef
500mg IV metronidazole thrice daily during five days.
Other names: Flagyl
Time frame: 90 days after surgery
A clinically relevant OSI is defined by the following criteria:
Time frame: 90 days
An OSI is defined by the CDC definition:
o The infection appears to be related to the operative procedure and infection involves any part of the anatomy (e.g., organs or spaces) other than the incision opened or manipulated during the operative procedure, and at least one of the following is present:
Time frame: 90 days
Isolated OSI is defined as an OSI without concurrent anastomotic leakage (pancreatojejunostomy, hepaticojejunostomy or gastrojejunostomy). The concept of an isolated OSI is used to separately classify abdominal infections without concurrent anastomotic leakage.
Time frame: 90 days
A superficial surgical site infection after surgery which involves superficial or deep soft tissue (skin, muscle or fascia, but no intra-abdominal tissue), and at least one of the following criteria is present:
Time frame: 90 days
Grade B or C postoperative pancreatic fistula (POPF) defined by the International Study Group of Pancreatic Surgery definition:
Grade A: Amylase >3 times upper limit of the institutional normal serum amylase value
Grade B: Grade A + persistant drainage >3 weeks, clinically relevant change in management of POPF, percutaneous or endoscopic drainage, angiographic procedures for bleeding, or signs of infection without organ failure.
Grade C: Grade A or B requiring reoperation, resulting in organ failure or death.
Time frame: 90 days
Grade A, B or C defined by the ISGLS definition:
Grade A: Bile leakage requiring no or little change in patients' clinical management.
Grade B: Bile leakage requiring a change in patients clinical management (eg, additional diagnostic or interventional procedures) but manageable without relaparotomy, or a Grade A bile leakage lasting for >1 week.
Grade C: Bile leakage requiring relaparotomy
Time frame: 90 days
Grade A, B or C defined by the ISGPS definition:
Grade A: Early (<24h after surgery), intra- or extraluminal, clinically mild.
Grade B: Early (<24h after surgery), intra- or extraluminal and clinically severe OR later (>24h after surgery), intra- or extraluminal and clincally mild.
Grade C: Late (>24h after surgery), intra- or extraluminal and clinically severe.
Time frame: 90 days
Grade A, B or C defined by the ISGPS definition:
Grade A: Until day 4-7 or replacement of feeding tube > 3 days after surgery
Grade B: Until day 8-14 or replacement of feeding tube > 7 days after surgery
Grade C: >day 14 or replacement of feeding tube > 14 after surgery
Time frame: 90 days
Defined as a positive blood culture obtained during a septic period (defined as two or more SIRS criteria)
Time frame: 90 days
Defined by a positive fecal culture for Clostridium difficile
Time frame: 90 days
Major complications is defined by a Clavien-Dindo score of ≥III.
Clavien-Dindo classification of Surgical Complications:
Grade I: Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions.
Grade II: Requiring pharmacological treatment with drugs other than such allowed for grade I complications.
Grade IIIa: Requiring surgical, endoscopic or radiological intervention not under general anesthesia Grade IIIb: Requiring surgical, endoscopic or radiological intervention under general anesthesia
Grade IVa: Life-threatening complication (including CNS complications)* requiring IC/ICU-management with single organ dysfunction (including dialysis).
Grade IVb: Life-threatening complication (including CNS complications)* requiring IC/ICU-management with multi organ dysfunction.
Grade V: Death of a patient
Time frame: 90 days
Reinterventions could be either radiological, surgical or endoscopic reinterventions
Time frame: 90 days
ICU admission
Time frame: 90 days
In days
Time frame: 90 days
Readmission into the hospital
Time frame: 90 days
In-hospital and 90-days mortality
Time frame: 5 days
Study protocol:
Time frame: 90 days
Rate of Antibiotic sensitivity patterns in bile cultures and cultures from surgical sites
Time frame: 90 days
Defined as the similarity of microorganisms between perioperative bile cultures and postoperative cultures from infectious sites.
Contact information is provided by the study sponsor or research team.
Leiden University Medical Center
Other
Standard Versus Pre-emptive Antibiotic Treatment to Reduce the Rate of Infectious Outcomes After Whipple's Procedure (SPARROW): a Multicenter, Randomized Controlled Trial
Acronym: SPARROW
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03021668
Chemoradiation, Chemotherapy Effects
Baltimore, Maryland, United States
View Trial DetailsNCT07636382
Advanced Cancer, Celiac Disease
Toronto, Ontario, Canada
View Trial DetailsNCT07737171
Digestive System Diseases, Digestive System Neoplasms
Houston, Texas, United States
View Trial DetailsNCT06411691
Colonic Diseases, Colonic Neoplasms
Baltimore, Maryland, United States
View Trial Details